

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/069838 A1

(51) International Patent Classification:
C07D 307/32 (2006.01)

Dongdaemun-ku, Seoul 130-060 (KR). **CHA, Dae-Won**
[KR/KR]; 469-250, Sanggal-ri, Giheung-eup, Yongin-si,
Gyeonggi-do 449-905 (KR).

(21) International Application Number:

PCT/KR2006/005372

(74) Agent: **ROH, Jae-Chull**; WAY with ROH Patent & Law
Office, 4F., Halla Building, #641-17, Yeoksam-dong,
Gangnam-gu, Seoul 135-909 (KR).

(22) International Filing Date:

11 December 2006 (11.12.2006)

(25) Filing Language:

Korean

(26) Publication Language:

English

(30) Priority Data:

10-2005-0123229

14 December 2005 (14.12.2005) KR

10-2006-0125230

11 December 2006 (11.12.2006) KR

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT,
LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **DONG-A
PHARM.CO., LTD.** [KR/KR]; 252, Yongdu-dong, Dong-
daemun-ku, Seoul 130-070 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Moon-Sung**
[KR/KR]; 101-1601, Hansolmaeul Cheonggu APT.,
Jeongja-dong, Bundang-gu, Seongnam-si, Gyeonggi-do
463-010 (KR). **KIM, Yong-Jik** [KR/KR]; 104-1402,
MinsokMaeul Ssangyong APT., Bora-ri, Giheung-eup,
Yongin-si, Gyeonggi-do 449-954 (KR). **CHOI, Jun-Ho**
[KR/KR]; 309-1105, Geumhwa Maeul APT., Sanggal-ri,
Giheung-eup, Yongin-si, Gyeonggi-do 449-905 (KR).
LIM, Hong-Gyu [KR/KR]; 17/1, 136-45, Jegi-dong,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A MANUFACTURING PROCESS OF 2',2'-DIFLUORONUCLEOSIDE AND INTERMEDIATE

(57) Abstract: The present invention relates to more improved process for preparing 2'-deoxy-2',2'-difluoronucleoside and its in-
termediate. The present invention provide a process for preparing an erythro enantiomer in greater than 98% purity, comprising
forming a lactone ring by hydrolyzing ethyl (3RS)-2,2-difluoro-3-hydroxy-3-(2,2-dimethyloxolan-4-yl)propionate is hydrolyzed in
the presence of hydrolysis reagents selected from acetic acid or chloroacetic acid, water and a mixture of organic solvents selected
from the group comprising acetonitrile, dioxane, tetrahydrofuran or toluene, introducing a substituted benzoyl protecting group
at the 3-position and 5-position, and recrystallizing said erythro enantiomer. Further, the present invention provides a process for
selectively preparing, in greater than 99% purity, a beta-anomer 2'-deoxy-2',2'-difluoronucleoside at the 3'-position and 5'-position
that are protected by a substituted benzoyl in a 2:3 alpha/beta anomeric ratio.

WO 2007/069838 A1